A brain implant let a paralyzed man feel and move his arm again

A New York man paralyzed from a diving accident can now lift a cup, scratch his nose, and handle fragile objects — thanks to a system of brain-implanted microchips and skin-worn stimulation patches. The results, published in Nature Medicine 2026 this July, mark the first peer-reviewed proof that a "double neural bypass" can not only restore movement but trigger the brain to rewire itself around a severed spinal cord.

The bypass

Keith Thomas, 45, from Massapequa, New York, suffered a C4–C5 spinal cord injury in July 2020 after a pool diving accident, leaving him quadriplegic. In March 2023, surgeons at the Feinstein Institutes for Medical Research spent 15 hours implanting five microchips across the brain regions controlling movement and touch sensation.

The system works in two directions at once. When Thomas thinks about moving his hand, a computer reads those brain signals in milliseconds and relays them to flexible electrodes on his forearm muscles, triggering movement. At the same time, pressure sensors on his fingertips feed touch data back to the brain, recreating the sensation of grip. The result is a closed loop — intention, motion, and feel — that bypasses the damaged spinal cord entirely.

The results

After 35 weeks of training, Thomas's right arm strength was up 86% and his left arm 62%. Those aren't abstract lab metrics: they translate to drinking from a cup unaided, wiping his face, and manipulating delicate objects with calibrated grip force.

The standout finding, though, is what happened when the device was turned off. Partial sensation in Thomas's right wrist persisted — meaning the brain had begun building new neural pathways on its own, a process called neuroplasticity. The bypass didn't just compensate for the injury; it encouraged the nervous system to partially repair itself.

Not a product yet

This is still an investigational device, not something available through a hospital or clinic. The implant surgery is a complex neurosurgical procedure, and months of intensive therapy are required before patients can use the system effectively. Neuralink holds FDA clearance for its own human trials (the Neuralink PRIME trial has been underway since 2023), but only a handful of implants have been reported in the US, and no UK clinical trial sites are currently listed in public registries.

The Feinstein case demonstrates something the field has debated for years: whether repeated electrical stimulation can genuinely trigger lasting neurological recovery, not just temporary motor assistance. One patient is not a clinical standard, but the Nature Medicine publication sets a new benchmark for what spinal cord research can demonstrate.